Prothya Biosolutions: Clinical Trials

26 trials sponsored by Prothya Biosolutions, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 5 terminated, 3 active not recruiting, 2 unknown. 11 Phase 3, 10 Phase 2, 7 Phase 4, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 311Completed 7, Terminated 3, Active not recruiting 1
Phase 210Completed 6, Active not recruiting 2, Terminated 2
Phase 47Completed 4, Active not recruiting 1, Terminated 1, Unknown 1
Phase 13Completed 3

Follow Prothya Biosolutions: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
Dupilumab - Atopic Dermatitis, Atopic Dermatitis Eczema
Phase 4Active not recruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2162023-08-142026-10-29
Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation
Cofact - Healthy Volunteers
Phase 1 / Phase 2CompletedProthya Biosolutions692021-11-122024-04-08
Add-on Intravenous Immunoglobulins in Early Myositis
Immune Globulin Intravenous (Human), Placebo - Inflammatory Myopathy, Idiopathic, Dermatomyositis
Phase 2 / Phase 3Active not recruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)442021-09-132026-02-27
Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)
ConvP, FFP - Covid19
Phase 3TerminatedErasmus Medical Center4202020-10-122022-04-01
Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)
Convalescent plasma - COVID-19
Phase 2 / Phase 3TerminatedErasmus Medical Center862020-04-082022-04-01
Data Registry of Auto Immune Hemolytic Anemia
Autoimmune Hemolytic Anemia
UnknownSanquin Research & Blood Bank Divisions7202019-07-122019-07-19
Apotransferrin in Patients With β-thalassemia
human apotransferrin - β-thalassemia Intermedia
Phase 2TerminatedProthya Biosolutions102019-03-212022-08-15
Pharmacokinetics of New HepBQuin
a human hepatitis B immunoglobulin solution for injection for intramuscular administration - Healthy
Phase 1CompletedProthya Biosolutions242019-03-202019-09-19
Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS
Wide Excision, Adalimumab Injection - Hidradenitis Suppurativa
Phase 4UnknownErasmus Medical Center1282018-07-312019-02-08
C1-inhibitor in Allergic ASThma Patients
C1-inhibitor, Saline, Antibiotics - Asthma
Phase 4TerminatedT. van der Poll372016-11-162020-06-24
Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
Natalizumab - Multiple Sclerosis
Phase 4CompletedAmsterdam UMC, location VUmc612016-11-032019-07-12
Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml
Intravenous immunoglobulin infusion - Primary Immunodeficiency
Phase 3CompletedProthya Biosolutions232013-12-012015-04-06
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II
C1-esterase inhibitor, Endotoxin - Innate Immune Response, Endotoxemia
Phase 3CompletedRadboud University Medical Center202013-09-012014-12-02
Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture
C1-esterase inhibitor, Saline 0.9% - Trauma, Inflammation
Phase 3TerminatedUMC Utrecht112012-04-012015-02-04
Apotransferrin in Atransferrinemia
Human apotransferrin - Congenital Atransferrinemia
Phase 2Active not recruitingProthya Biosolutions52010-12-012026-09-16
Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy
Intravenous Immunoglobulins, plasma volume expander - Myocardial Diseases, Parvovirus B19, Human
Phase 3CompletedProthya Biosolutions502009-11-012018-08-29
Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
intravenous immunoglobulins, antibiotics - IgG Deficiency, Infections
Phase 4CompletedProthya Biosolutions552007-11-012015-04-06
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
C1 inhibitor concentrate (C1-esteraseremmer-N) - Angioedema
Phase 2 / Phase 3CompletedProthya Biosolutions62006-11-012009-05-04
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
C1 inhibitor concentrate (C1-esteraseremmer-N) - Angioedema
Phase 3CompletedProthya Biosolutions152006-02-012009-05-04
Kinetics, Efficacy and Safety of C1-Esteraseremmer-N
C1 inhibitor concentrate - Hereditary Angioedema Type I, Angioneurotic Edema
Phase 2CompletedProthya Biosolutions122005-09-012009-05-04

Showing 20 of 26. Sign in to see all of them.

Conditions studied

Angioedema (3)  ·  Hereditary Angioedema Types I and II (3)  ·  Acquired angioedema (2)  ·  Angioedemas, Hereditary (2)  ·  COVID-19 (2)  ·  Inflammation (2)  ·  Sepsis (2)  ·  Agammaglobulinemia (1)  ·  Anemia (1)  ·  Anemia, Hemolytic, Autoimmune (1)  ·  Antisynthetase syndrome (1)  ·  Asthma (1)  ·  Cardiomyopathies (1)  ·  Congenital atransferrinemia (1)  ·  Dermatitis, Atopic (1)

Interventions

Complement C1 Inhibitor Protein (3)  ·  Immunoglobulins, Intravenous (3)  ·  Sodium Chloride (3)  ·  Anti-Bacterial Agents (2)  ·  Adalimumab (1)  ·  Ciprofloxacin (1)  ·  Endotoxins (1)  ·  Factor IX (1)  ·  Injections (1)  ·  Mannose-Binding Lectin (1)  ·  Metronidazole (1)  ·  Natalizumab (1)  ·  Plasma Substitutes (1)  ·  SERPING1 protein, human (1)  ·  Vancomycin (1)

Countries

Netherlands (22)  ·  Germany (2)  ·  Belgium (1)  ·  Italy (1)  ·  Poland (1)  ·  Spain (1)

Top investigators

M. M. Levi, Prof. Dr. (3)  ·  Bart Rijnders, MD, PhD (2)  ·  P FW Strengers, MD (2)  ·  Alberto Piperno, MD, PhD (1)  ·  Bart Biemond, MD, PhD (1)  ·  DirkJan Hijnen, MD PhD (1)  ·  E AM Sanders, PhD, MD (1)  ·  E P Mauser-Bunschoten, MD, PdD (1)  ·  F P Kroon, PhD, MD (1)  ·  H N Caron (1)  ·  Hans Hoeven, Prof (1)  ·  J T van Dissel, PhD, MD (1)  ·  Jan Prins, MD PhD (1)

Results publications

PMID 21988742, PMID 28515092, PMID 33044747, PMID 33347677, PMID 34013969, PMID 34303860, PMID 35546145, PMID 36734509, PMID 37162745

NIH funding

2023 (1)